| Primary |
| Product Used For Unknown Indication |
64.2% |
| Bronchitis |
5.0% |
| Lung Disorder |
4.6% |
| Urinary Tract Infection |
3.3% |
| Pneumonia |
2.4% |
| Endocarditis |
2.2% |
| Atrial Fibrillation |
2.0% |
| Hypertension |
2.0% |
| Lung Infection |
1.5% |
| Meningitis |
1.5% |
| Prostatitis |
1.5% |
| Erysipelas |
1.3% |
| Febrile Infection |
1.3% |
| Sepsis |
1.3% |
| Arthritis Bacterial |
1.1% |
| Mastoiditis |
1.1% |
| Pyrexia |
1.1% |
| Brain Abscess |
0.9% |
| Bronchial Disorder |
0.9% |
| Intervertebral Discitis |
0.9% |
|
| Renal Failure Acute |
12.0% |
| Acute Generalised Exanthematous Pustulosis |
10.0% |
| Hepatocellular Injury |
10.0% |
| Drug Reaction With Eosinophilia And Systemic Symptoms |
9.0% |
| International Normalised Ratio Increased |
8.0% |
| Toxic Skin Eruption |
8.0% |
| Hepatitis |
4.0% |
| Pancytopenia |
4.0% |
| Rash |
4.0% |
| Toxic Epidermal Necrolysis |
4.0% |
| Cholelithiasis |
3.0% |
| Rash Maculo-papular |
3.0% |
| Renal Failure |
3.0% |
| Thrombocytopenia |
3.0% |
| Transaminases Increased |
3.0% |
| Tubulointerstitial Nephritis |
3.0% |
| Vomiting |
3.0% |
| Disturbance In Attention |
2.0% |
| Encephalopathy |
2.0% |
| Haematoma |
2.0% |
|
| Secondary |
| Product Used For Unknown Indication |
44.6% |
| Pneumonia Necrotising |
7.9% |
| Lung Disorder |
7.5% |
| Hypertension |
4.5% |
| Prostatitis |
3.2% |
| Pyrexia |
3.2% |
| Sepsis |
3.2% |
| Hiv Infection |
2.6% |
| Infection |
2.6% |
| Pain |
2.4% |
| Urinary Tract Infection |
2.4% |
| Cough |
2.1% |
| Lung Infection |
1.9% |
| Bronchial Disorder |
1.7% |
| Bronchitis |
1.7% |
| Epilepsy |
1.7% |
| Osteitis |
1.7% |
| Plasma Cell Myeloma |
1.7% |
| Pneumonia |
1.7% |
| Intervertebral Discitis |
1.5% |
|
| Drug Reaction With Eosinophilia And Systemic Symptoms |
12.0% |
| Neutropenia |
12.0% |
| Thrombocytopenia |
8.7% |
| Renal Failure Acute |
6.5% |
| Septic Shock |
6.5% |
| Stevens-johnson Syndrome |
6.5% |
| Renal Failure |
4.3% |
| Renal Tubular Necrosis |
4.3% |
| Skin Test Negative |
4.3% |
| Toxic Skin Eruption |
4.3% |
| Urticaria Papular |
4.3% |
| Agranulocytosis |
3.3% |
| Coombs Negative Haemolytic Anaemia |
3.3% |
| Hepatocellular Injury |
3.3% |
| Pyrexia |
3.3% |
| Rash Morbilliform |
3.3% |
| Toxic Epidermal Necrolysis |
3.3% |
| Acute Generalised Exanthematous Pustulosis |
2.2% |
| Cholelithiasis |
2.2% |
| Cholestasis |
2.2% |
|
| Concomitant |
| Product Used For Unknown Indication |
29.8% |
| Acute Lymphocytic Leukaemia |
8.5% |
| Drug Use For Unknown Indication |
5.6% |
| Osteomyelitis |
5.6% |
| Pyrexia |
5.1% |
| Rhabdomyosarcoma |
4.5% |
| Staphylococcal Infection |
4.5% |
| Hypertension |
3.8% |
| Pain |
3.6% |
| Infection Prophylaxis |
3.1% |
| Interstitial Lung Disease |
3.1% |
| Non-small Cell Lung Cancer |
3.1% |
| Lung Disorder |
2.7% |
| Metastases To Peritoneum |
2.7% |
| Pneumonia |
2.7% |
| Antibiotic Therapy |
2.5% |
| Urinary Tract Infection |
2.5% |
| Abdominal Pain |
2.2% |
| Haematoma Infection |
2.2% |
| Rash |
2.2% |
|
| Urticaria |
14.0% |
| Renal Failure Acute |
7.0% |
| Febrile Bone Marrow Aplasia |
5.3% |
| Hypomagnesaemia |
5.3% |
| Mucosal Inflammation |
5.3% |
| Pancreatitis Acute |
5.3% |
| Pyrexia |
5.3% |
| Rash |
5.3% |
| Respiratory Distress |
5.3% |
| Thrombocytopenia |
5.3% |
| Thrombotic Microangiopathy |
5.3% |
| Acute Coronary Syndrome |
3.5% |
| Acute Generalised Exanthematous Pustulosis |
3.5% |
| Drug Reaction With Eosinophilia And Systemic Symptoms |
3.5% |
| Encephalopathy |
3.5% |
| Hepatocellular Injury |
3.5% |
| Hypercalcaemia |
3.5% |
| Lung Disorder |
3.5% |
| Lung Infection |
3.5% |
| Off Label Use |
3.5% |
|
| Interacting |
| Bronchitis |
18.2% |
| Diffuse Large B-cell Lymphoma |
18.2% |
| Pneumonia |
18.2% |
| Product Used For Unknown Indication |
18.2% |
| Heart Transplant |
9.1% |
| Pyrexia |
9.1% |
| Sepsis |
9.1% |
|
| Drug Interaction |
20.0% |
| International Normalised Ratio Increased |
20.0% |
| Overdose |
20.0% |
| Rash |
20.0% |
| Renal Failure Acute |
20.0% |
|
